[go: up one dir, main page]

ZA200709048B - Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse - Google Patents

Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse

Info

Publication number
ZA200709048B
ZA200709048B ZA200709048A ZA200709048A ZA200709048B ZA 200709048 B ZA200709048 B ZA 200709048B ZA 200709048 A ZA200709048 A ZA 200709048A ZA 200709048 A ZA200709048 A ZA 200709048A ZA 200709048 B ZA200709048 B ZA 200709048B
Authority
ZA
South Africa
Prior art keywords
substance abuse
chloride channel
stimulant substance
alcohol
treat alcohol
Prior art date
Application number
ZA200709048A
Other languages
English (en)
Inventor
Legarda Ibanez Juan Jose
Original Assignee
Hythiam Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hythiam Inc filed Critical Hythiam Inc
Publication of ZA200709048B publication Critical patent/ZA200709048B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA200709048A 2005-04-21 2007-10-19 Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse ZA200709048B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/111,435 US20050192271A1 (en) 2003-07-15 2005-04-21 Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse

Publications (1)

Publication Number Publication Date
ZA200709048B true ZA200709048B (en) 2008-09-25

Family

ID=37215204

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200709048A ZA200709048B (en) 2005-04-21 2007-10-19 Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse

Country Status (17)

Country Link
US (3) US20050192271A1 (xx)
EP (1) EP1742639B1 (xx)
JP (1) JP2008536921A (xx)
KR (1) KR20080004615A (xx)
CN (1) CN101203225A (xx)
AT (1) ATE539755T1 (xx)
AU (1) AU2006240324B2 (xx)
BR (1) BRPI0610038A2 (xx)
CA (1) CA2605918A1 (xx)
CR (1) CR9444A (xx)
IL (1) IL186641A0 (xx)
MX (1) MX2007012993A (xx)
NO (1) NO20075562L (xx)
NZ (1) NZ562585A (xx)
RU (1) RU2007143053A (xx)
WO (1) WO2006115743A2 (xx)
ZA (1) ZA200709048B (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050192271A1 (en) * 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
RU2468799C1 (ru) * 2011-08-03 2012-12-10 Общество с ограниченной ответственностью "Урал Крафт" Способ купирования алкогольного абстинентного синдрома посредством блокады бензодиазепиновых рецепторов
WO2015054730A1 (en) * 2013-10-14 2015-04-23 Palmaya Pty Ltd Compositions and methods of administering same
WO2017210502A1 (en) * 2016-06-03 2017-12-07 Yale University Methods and apparatus for predicting depression treatment outcomes
CA3095682A1 (en) * 2018-04-06 2019-10-10 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of substance use disorders

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028611A (en) * 1989-06-29 1991-07-02 The Regents Of The University Of Minnesota Treatment for cocaine use
US5519017A (en) * 1990-03-29 1996-05-21 Lts Lohmann Therapie-Systeme Gmbh + Co. Kg Pharmaceutic formulation for the treatment of alcoholism
SE9100860D0 (sv) * 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use
DE4123106A1 (de) * 1991-07-09 1993-01-14 Schering Ag Arzneimittel zur behandlung von entzugssymptomen
US5229120A (en) * 1992-02-05 1993-07-20 Devincent James F Treatment for cocaine abuse
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
GB9420010D0 (en) * 1994-10-01 1994-11-16 Marck Sharp & Dohme Limited Nucleic acids
CA2326419A1 (en) * 1998-03-31 1999-10-07 Shionogi & Co., Ltd. Process for producing 5-hydroxybenzo[b]thiophene-3-carboxylic acid derivatives
WO1999061014A2 (en) 1998-05-28 1999-12-02 Sepracor Inc. Compositions and methods employing r(-) fluoxetine and other active ingredients
US6541520B1 (en) * 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
US6890951B2 (en) * 1998-08-05 2005-05-10 Brookhaven Science Associates Llc Treatment of addiction and addiction-related behavior
US6339106B1 (en) * 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
EP1133299A1 (en) * 1998-11-23 2001-09-19 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
US6489341B1 (en) * 1999-06-02 2002-12-03 Sepracor Inc. Methods for the treatment of neuroleptic and related disorders using sertindole derivatives
US6399826B1 (en) * 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US6750235B1 (en) * 1999-09-30 2004-06-15 The General Hospital Corporation Pramipexole as a treatment for cocaine craving
EP1125579A3 (en) * 2000-01-18 2003-01-02 Pfizer Products Inc. Uses of agrp-melanocortin receptor binding modulating compounds
AU2002226427B2 (en) * 2001-01-17 2006-11-16 Hythiam, Inc. Use of flumazenil in developing a drug for the treatment of alcohol dependence
US20050192271A1 (en) 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
JP4272885B2 (ja) * 2001-02-15 2009-06-03 ハイチアム，インコーポレイテッド コカイン依存症治療用薬剤
US20020150632A1 (en) * 2001-04-12 2002-10-17 Nick Scott Psychonutracological method for craving reduction in humans
FR2827172B1 (fr) * 2001-07-13 2004-07-02 Pf Medicament Derives de pyridin-2-yl-methylamine pour le traitement de la dependance aux opioides
US20030176456A1 (en) * 2001-12-21 2003-09-18 June Harry L. Methods for reducing alcohol cravings in chronic alcoholics
US6740677B2 (en) * 2002-08-19 2004-05-25 Hong Xue Methods of treating benzodiazepine site (BZD-S) associated syndromes using 2′ hydroxyflavonoids
DE602004029993D1 (de) * 2003-02-27 2010-12-23 Eisai R&D Man Co Ltd Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit
US20050031668A1 (en) * 2003-05-30 2005-02-10 Patel Rajesh A. Implantable polymeric device for sustained release of nalmefene
JP2005332453A (ja) * 2004-05-19 2005-12-02 Hitachi Ltd 情報再生装置及び情報再生方法
US20060167723A1 (en) * 2005-01-21 2006-07-27 Berg L M Method of treating dependencies
EP1868593A2 (en) 2005-04-07 2007-12-26 Hythiam, Inc. Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence

Also Published As

Publication number Publication date
CA2605918A1 (en) 2006-11-02
NZ562585A (en) 2010-04-30
CR9444A (es) 2008-02-20
AU2006240324B2 (en) 2010-02-25
EP1742639A4 (en) 2008-05-07
WO2006115743A2 (en) 2006-11-02
MX2007012993A (es) 2008-03-11
AU2006240324A1 (en) 2006-11-02
CN101203225A (zh) 2008-06-18
JP2008536921A (ja) 2008-09-11
IL186641A0 (en) 2008-06-05
US7863267B2 (en) 2011-01-04
WO2006115743A3 (en) 2007-06-28
US20050192271A1 (en) 2005-09-01
US20080207599A1 (en) 2008-08-28
EP1742639A2 (en) 2007-01-17
US20090215751A1 (en) 2009-08-27
RU2007143053A (ru) 2009-05-27
KR20080004615A (ko) 2008-01-09
EP1742639B1 (en) 2012-01-04
ATE539755T1 (de) 2012-01-15
NO20075562L (no) 2007-12-07
BRPI0610038A2 (pt) 2016-11-29

Similar Documents

Publication Publication Date Title
SG155188A1 (en) Pyrrole derivatives as pharmaceutical agents
EA200901308A1 (ru) Ингибиторы белка, активирующего 5-липоксигеназу (flap)
NO20090157L (no) Tienpyrimidiner anvendelige som modulatorer av ionekanaler
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA200801163A1 (ru) Ингибиторы протеина, активирующего 5-липоксигеназу (flap)
WO2009044173A3 (en) Methods of treating cancer using notch pathway inhibitors
SG146653A1 (en) Methods and reagents for the treatment of immunoinflammatory disorders
EA200801164A2 (ru) Ингибиторы протеина, активирующего 5-липоксигеназу (flap)
TW200745124A (en) Azepinoindole derivatives as pharmaceutical agents
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
WO2010059004A3 (ko) 스네일-p53 간의 결합을 저해하는 화합물 및 이를 유효성분으로 함유하는 암질환 치료제
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
DK1654253T3 (da) Substituerede 3-pyrrolidinindolderivater
EA200700074A1 (ru) Способ повышения скорости заживления повреждения ( варианты ), устройство доставки перекиси водорода и композиция для лечения повреждений у млекопитающих
ZA200709048B (en) Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
DE502005005636D1 (en) Spirocyclische cyclohexan-derivate
NO20065936L (no) Sulfonyletylfosfordiamidater for anvendelse ved behandling av cancer.
WO2008155390A3 (en) Use of inhibitors of sirtuins and/or ampk for the preparation of a medicament for the treatment of polyalanine diseases.
EA200700407A1 (ru) Производные хиназолина и их использования при лечении тромбоцитемии
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
WO2007005940A3 (en) Combinations of eszopiclone and didesmethylsibutramine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
EP1603595A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRUG INDEPENDENCE
WO2003079748A3 (en) Potentiation of cancer therapies by znf217 inhibition
BRPI0507912A (pt) método para o tratamento ou a prevenção de osteoporose em um indivìduo que sofra de renovação óssea aumentada, e, uso de um composto terapeuticamente ativo
NO20063320L (no) Anvendelse av gaboxadol for behandling av insomni